Inhaled insulin in pregnancy: A case series supporting feasibility and clinical potential for pregnant people with diabetes
Related Experiment Video
Updated: Aug 15, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Michaela C Rickert1, Linda A Barbour2, Bruce W Bode3
1Division of Maternal Fetal Medicine Oregon Health and Sciences University Portland Oregon USA.
Background:
Dose conversions, dose titration, and efficacy of inhaled insulin (TI) compared to rapid-acting insulin (RAA) have not been studied in pregnancy. This case series demonstrates the various management approaches of TI use in pregnant patients with preexisting diabetes. Minimal data are available on the use of TI in pregnancy. Given the scarcity of data in pregnancy, our objective was to describe approaches of TI use in diabetes management during pregnancy.
Research Design And Methods:
Case series.
Results:
This case series demonstrates the versatility of TI use in pregnancy, including routine meal coverage, postprandial hyperglycemia corrections, and as a feasible alternative to RAA when compliance or consistency of use with subcutaneous injections is a challenge. In this limited case series, TI appears to be a safe alternative to RAA in pregnancy.
Conclusions:
TI appears to be a feasible and acceptable alternative to RAA in pregnancy.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into rapid-acting...